Biome Australia (ASX:BIO) has achieved a milestone result in the 2025 financial year, reporting its first full-year net profit since its founding in 2018.
The microbiome health company recorded a net profit after tax of $214,656, supported by a 41.6 per cent jump in sales revenue to $18.4 million, marking a breakthrough year of growth and profitability.
The performance capped off a record June quarter in which sales exceeded $5 million, including a single-month high of $2.1 million. International sales reached $1.5 million, up nearly 70 per cent on the prior year, highlighting the company’s expanding global footprint. Gross profit climbed to $11.25 million with margins improving to 61.1 per cent, while earnings (excluding share-based payments) came in at $931,000, the sixth consecutive positive quarter.
Founder and managing director, Blair Vega Norfolk, described the result as the culmination of seven years of work to establish a sustainable, high-growth business. “I am absolutely thrilled to announce our first full year of profitability since founding Biome in 2018,” Norfolk said. “What excites me most is that we’ve achieved this through high-quality customer service, education and delivering meaningful health outcomes for our patients and customers.”
A cornerstone of the company’s success is its Activated Probiotics brand, which secured the number two position in total probiotic revenue in Australian community pharmacies, according to IQVIA data. Domestic sell-through increased by more than 50 per cent in 2025, making it the category’s fastest-growing brand. Norfolk credited this performance to Biome’s focus on innovation, clinical validation, and strong professional education programs.
The company also achieved significant progress in international markets, forging transformational distribution partnerships across Canada, Ireland, the UK, and New Zealand. Agreements with major Canadian health retailers, Uniphar in Ireland, and Propharma in New Zealand are expected to give Biome access to thousands of new pharmacy and health food outlets from FY26, providing a scalable platform for growth.
In June 2025, the company launched its Activated Therapeutics range, a practitioner-only line of targeted probiotic formulations addressing perimenopause, gastrointestinal repair, acid reflux, and weight management. It also introduced seven new products across its portfolio during the year. Another milestone was the registration of its proprietary probiotic strain, Lactobacillus plantarum BMB18, with the German culture bank DSMZ, which opens up future opportunities for licensing and commercialisation.
Biome’s Vision 27 strategy, which targets at least $75 million in cumulative sales between 2025 and 2027, remains firmly on track. Entering 2026, the company reported an annualised revenue run-rate of more than $20 million, underpinned by strong momentum in both domestic and international markets. Norfolk said the company is now poised to transition from an emerging player into a global leader in probiotics and targeted health solutions.
“After seven years of building this business, seeing us transition into a sustainable, profitable growth company, we are now entering the next phase to becoming a leading global company in probiotics and targeted health solutions for many years to come,” he said.